BLRX - BioLineRx Price-to-Projected Revenue Ratio

BioLineRx Ltd. (BLRX) hedges biotech risks by combining early-stage research with the sale of drugs for genetic and oncological pathologies. The forward revenue multiple demonstrates a gradual decline in asset valuation, with the metric currently standing at 4.80. The drug Aphexda optimizes stem cell collection in hematology, while the development strategy is based on Asian distribution without mergers.

BioLineRx Ltd - BLRX Projected Price to Revenue (period 03/28/2024 - 11/13/2026)

Comprehensive metric breakdowns and analytics for BioLineRx Corporation (BLRX)

- market price and analyst price targets:

Price Chart BioLineRx|BLRX - Price Target Chart

- market capitalization statistics:

Market Value BioLineRx Corporation|BLRX - Total Enterprise Value

- book value of equity indicators:

Book Value per Share BioLineRx|BLRX - Book Value of Business|Market Cap to Net Assets Ratio biolinerx.com|BLRX - Company Assets

- debt and liquidity data:

- financial results and valuation multiples details:

BLRX - Final Profit|Projected Future Earnings BioLineRx Ltd.|BLRX - P/E Multiple|Future Price to Earnings BioLineRx Corp|BLRX - Market Cap to Earnings and Growth Ratio|Enterprise Value to EBITDA Ratio BioLineRx Corporation|BLRX - Profit before interest, taxes and amortization|Net earnings per share (EPS TTM) BioLineRx|BLRX - Earnings per share for the last twelve months|Quarterly EPS earnings growth biolinerx.com|BLRX - Expected net earnings per share growth this year|Net earnings per share growth forecast for next year BioLineRx Ltd.

- revenue and sales proceeds data:

BLRX - Company Total Revenue|Company Projected Revenue BioLineRx|BLRX - Price-to-Revenue Ratio|Forward P/S Multiple BioLineRx Corporation

General company analysis:BioLineRx BLRX

This ratio determines the market value of the business relative to its expected annual sales, allowing an investor to assess the extent of the premium paid for future cash flow. By analyzing the forward P/S metric, you can see the capitalization dynamics of BioLineRx Ltd. (BLRX) as the company transitions to commercial sales of its oncology drug and expands distribution across the US and Asia.

Key competitors

Price-to-Projected Revenue Ratio Incyte INCY|Hutchison MediPharma - Price-to-Projected Revenue Ratio|NUVB - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio Day One Biopharmaceuticals Inc|MNPR: Forward P/S Multiple|Projected Price to Revenue inhibrx.com INBX|Forward Price-to-Revenue Multiple IMAB|Market Cap to Future Revenue Ratio Fennec Pharma FENC|Forward Price-to-Revenue Multiple HRTX (Heron Therapeutics)|NVCT (Nuvectis Pharma, Inc) - Forward Price to Sales|Coherus Biosciences - Forward Price-to-Revenue Multiple|Price to Expected Revenue Ratio CRBP (corbuspharma.com)|Cardiff Oncology Corp - Forward P/S Multiple|Forward Price to Sales BYSI (BeyondSpring, Inc.)|BCAB: Forward P/S Multiple|Market Cap to Future Revenue Ratio Lixte Biotechnology, Inc. (LIXT)|Price-to-Projected Revenue Ratio Citius Pharmaceuticals Inc.|CLRB: Forward Price to Sales|Forward P/S Multiple CANF|Forward P/S Multiple aprea.com (APRE)|Price-to-Projected Revenue Ratio Kazia Therapeutics Limited KZIA|SLXN (Silexion Therapeutics Corp.) - Future Price to Revenue|NCNA: Forward Price-to-Revenue Multiple|Market Cap to Future Revenue Ratio chimerix.com|CYCC: Forward P/S Multiple|GTHX (G1 Therapeutics) - Price-to-Projected Revenue Ratio|KRON (Kronos Bio Corp) - Forward P/S Multiple|Kintara Pharma (KTRA) - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio Oncternal Therapeutics (ONCT)|PRTG - Market Cap to Future Revenue Ratio